MARKET

MREO

MREO

MEREO BIOPHARMA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.200
+0.070
+2.24%
Closed 16:00 09/20 EDT
OPEN
3.220
PREV CLOSE
3.130
HIGH
3.438
LOW
3.200
VOLUME
3.87K
TURNOVER
--
52 WEEK HIGH
8.48
52 WEEK LOW
2.180
MARKET CAP
69.59M
P/E (TTM)
-1.4678
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MREO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

MREO News

  • Mereo BioPharma's (MREO) CEO Denise Scots-Knight on 2019 Interim Financial Results and Corporate Update Conference Call
  • Seeking Alpha - Transcript.4d ago
  • Mereo BioPharma Group reports 1H results
  • seekingalpha.4d ago
  • Mereo BioPharma Group plc 2019 Q2 - Results - Earnings Call Slides
  • Seeking Alpha - Article.5d ago
  • Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2019 and Provides Corporate Update
  • GlobeNewswire.5d ago

More

Industry

Biotechnology & Medical Research
+0.62%
Pharmaceuticals & Medical Research
+0.95%

Hot Stocks

Name
Price
%Change

About MREO

Mereo BioPharma Group PLC is a United Kingdom-based biopharmaceutical company. The Company is focused on development and commercialization of therapeutics for patients with rare diseases. Its pipeline includes BPS-804, MPH-966, BCT-197, BGS-649, Navicixizumab and Etigilimab. BPS-804 (setrusumab) is being developed to improve bone strength and thereby reduce fractures in the orphan disease osteogenesis imperfecta (OI). MPH-966 (alvelestat) is being developed for alpha-1 antitrypsin deficiency (AATD). BGS-649 (leflutrozole) is being developed for the treatment of obese men with hypogonadotropic hypogonadism (HH). BCT-197 (acumapimod) is being developed as a therapy for acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Navicixizumab is being developed for platinum-resistant ovarian cancer. Etigilimab is being developed for advanced or metastatic solid tumors.
More

Webull offers Mereo BioPharma Group PLC (MREO) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.